Company news
Disc Medicine, Inc. news in 2025
Disc Medicine, Inc.'s news releases, calls and decks from 2025, newest first.
2025 ASH Management Call FINAL
December 8, 2025
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
December 5, 2025
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
November 2, 2025
Disc Medicine to Participate in Upcoming Investor Conferences
October 30, 2025
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
October 20, 2025
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
October 19, 2025
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
October 16, 2025
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
October 15, 2025
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
September 29, 2025
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
OrbiMed Promotes Mona Ashiya to General Partner
July 22, 2025
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
July 20, 2025
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
July 13, 2025
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
June 11, 2025
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
May 13, 2025
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 12, 2025
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
April 28, 2025
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 26, 2025
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
January 21, 2025
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
January 20, 2025
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 20, 2025
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
January 19, 2025
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
January 16, 2025
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
January 9, 2025
Decks in 2025
- 2025 ASH Management Call
Conference · 31 slides · Dec 8, 2025
- Investor Presentation (October 2025)
Investor deck · 61 slides · Oct 20, 2025